Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
SYK is a novel target for treatment of Epstein Barr virus-infected B cell lymphomas in post-transplant lymphoproliferative disease. 7th American Transplant Congress Hatton, O., Vaysberg, M., Sharman, J., Krams, S. M., Esquivel, C. O., Martinez, O. M. WILEY-BLACKWELL. 2007: 317–318
View details for Web of Science ID 000246370201087